Lilly announces the Mounjaro heart indication, built on a head-to-head trial

Eli Lilly said on August 28, 2026 that the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events ^[1]. Mounjaro was already approved alongside diet and exercise to improve blood sugar in adults and children 10 and older with type 2 diabetes ^[1].

The approval rests on SURPASS-CVOT (NCT04255433), which Lilly describes as the first cardiovascular outcomes trial to compare two incretin medicines head-to-head rather than against placebo ^[1]. The trial randomized 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease 1:1 across 640 sites in 30 countries ^[1]. One group received Mounjaro at 15 mg or the maximum tolerated dose once weekly; the other received Trulicity (dulaglutide) 1.5 mg once weekly, a GLP-1 medicine that already carries an approved cardiovascular indication ^[1].

What the numbers showed

Over a median follow-up of 210.1 weeks — about four years, within a trial that ran roughly five years — tirzepatide met the study's primary goal of non-inferiority to dulaglutide for first MACE-3 events ^[1]. The hazard ratio was 0.92 (95.3% confidence interval 0.83 to 1.01), which Lilly describes as an 8% lower rate of cardiovascular death, heart attack or stroke ^[1]. Because the confidence interval crossed 1.0, superiority over dulaglutide was not established ^[1].

The reported non-inferiority p-value was 0.007, and all-cause death was 8.5% with tirzepatide versus 10.1% with dulaglutide, a hazard ratio of 0.84. Lilly's announcement does not break out those mortality figures; it states that full SURPASS-CVOT results were published in the New England Journal of Medicine ^[1].

On safety, Lilly said tolerability was generally consistent with tirzepatide's established profile, with the most common adverse events being gastrointestinal, generally mild to moderate, and occurring mainly during dose escalation ^[1].

The FDA-approved labeling on DailyMed was updated August 27, 2026, and lists the MACE indication as a recent major change dated 08/2026, along with revisions to the recommended dosage section and a new warning on diabetic retinopathy complications in patients with a history of diabetic retinopathy ^[2]. Mounjaro still carries a boxed warning about the risk of thyroid C-cell tumors seen in rats and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[2].

Why it matters for patients

For adults with type 2 diabetes, this changes what the label says a drug is proven to do, not just what it does to A1C and weight. Lilly cites an estimate that as many as one in three U.S. adults with type 2 diabetes have undetected cardiovascular disease ^[1]. An FDA-recognized indication is often what insurers and prescribers point to when deciding coverage and treatment choices, though the sources do not say whether or how insurers will respond.

The design also shapes how the result should be read. Because the comparison was against an active drug with known heart benefit rather than a sugar pill, the trial cannot say how much tirzepatide lowers risk compared with no treatment at all ^[1]. It showed tirzepatide was not worse than dulaglutide, and did not prove it was better ^[1].

One limit is worth noting: the new indication applies to Mounjaro in adults with type 2 diabetes at high cardiovascular risk ^[1][2]. The sources say nothing about whether the same data apply to Zepbound, the tirzepatide brand used for weight management, so that is not yet known from this announcement.

What happens next

Data from SURPASS-CVOT have already been added to Mounjaro's product information in the European Union, and regulatory submissions based on the trial are under review in additional markets, with no decision dates given ^[1]. Updated U.S. prescribing information and the Medication Guide reflecting the August 2026 changes are already posted ^[2].